EverSource Wealth Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
– Sell
-75
Closed -$1.56K – 4257
2025
Q1
$1.56K Sell
75
-219
-74% -$5.5K ﹤0.01% 3048
2024
Q4
$6.92K Buy
294
+73
+33% +$1.8K ﹤0.01% 2186
2024
Q3
$5.66K Sell
221
-594
-73% -$15.1K ﹤0.01% 2180
2024
Q2
$22K Sell
815
-875
-52% -$22.1K ﹤0.01% 1462
2024
Q1
$39.4K Buy
+1,690
New +$50.8K ﹤0.01% 1077
2023
Q2
– Sell
-20
Closed -$601 – 2499
2023
Q1
$601 Sell
20
-40
-67% -$1.24K ﹤0.01% 2189
2022
Q4
$1.69K Hold
60
– – ﹤0.01% 1961
2022
Q3
$2K Hold
60
– – ﹤0.01% 1621
2022
Q2
$2K Hold
60
– – ﹤0.01% 1466
2022
Q1
$3K Hold
60
– – ﹤0.01% 1390
2021
Q4
$4K Buy
+60
New +$4.15K ﹤0.01% 1303

Other funds holding ARKG

EverSource Wealth Advisors's ARKG Position: Q2 2025 in Review

EverSource Wealth Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2025, closing a stake of 75 shares — an estimated $1.56K sold.

EverSource Wealth Advisors first reported a position in ARKG in Q4 2021 and held it in 11 quarters. The position peaked at $39.4K in Q1 2024. 216 funds tracked by Wall St. Rank hold ARKG as of Q2 2025.

  • EverSource Wealth Advisors reported no remaining ARK Genomic Revolution ETF position as of Q2 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 75 ARK Genomic Revolution ETF shares in Q2 2025, an estimated $1.56K.
  • EverSource Wealth Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2021 and held it in 11 quarters.
  • EverSource Wealth Advisors's ARK Genomic Revolution ETF position peaked at $39.4K in Q1 2024.
  • 216 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2025.

Based on EverSource Wealth Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.